Lepra İmmünopatogenezi
References
Mi, Z., Liu, H., Zhang, F. (2024). Advances in the pathogenic, genetic and immunological studies of leprosy. hLife, 2(1), 6-17. doi.org/10.1016/j.hlife.2023.10.003.
Cabral, N., de Figueiredo, V., Gandini, M., de Souza, C. F., Medeiros, R. A., Lery, L. M. S., Lara FA, de Macedo CS., Pessolani MCV., Pereira, G. M. B. (2022). Modulation of the response to Mycobacterium leprae and pathogenesis of leprosy. Frontiers in microbiology, 2;13: 918009. doi: 10.3389/fmicb.2022.918009.
Mi, Z., Liu, H., Zhang, F. (2020). Advances in the immunology and genetics of leprosy. Frontiers in immunology, 16:11:567. doi: 10.3389/fimmu.2020.005674
World Health Organization. Global leprosy (Hansen disease) update, 2024: Beyond zero cases—what elimination of leprosy really means. Wkly Epidemiol Rec. 2025;100(37):365-384. https://iris.who.int/server/api/core/bitstreams/b4ad088c-c66a-46b9-ac80-30576097b57b/content (Erişim tarihi: 02.07.2026).
Grijsen, M. L., Nguyen, T. H., Pinheiro, R. O., Singh, P., Lambert, S. M., Walker, S. L., Geluk, A. (2024). The Leprosy. Nature Reviews Disease Primers, 28:10(1):90. doi: 10.1038/s41572-024-00575-1.
Hasker, E., Cambau, E., Geluk, A., de Jong, B. C., Barreto, J., van Brakel, W., ... & Vollset, M. (2025). Interrupting transmission of Mycobacterium leprae: synthesis of new evidence and research recommendations. Leprosy Review, 96(2), e2025034.
World Health Organization. Target product profile for a diagnostic test to detect Mycobacterium leprae infection among asymptomatic household and familial contacts of leprosy patients. 2023.
https://www.who.int/publications/i/item/9789240074231 (Erişim tarihi: 02.07.2026).
Ansari A, Kumar R, Ray SK, Patel A, Dwivedi P, Ghosh A, Machado E, Suffys PN, Singh P. (2025) Genetic variability, genotyping, and genomics of Mycobacterium leprae. FEMS Microbiol Rev. Jan 14;49:fuaf012. doi: 10.1093/femsre/fuaf012.
Aslan, G. (2023). Lepra: İhmal Edilmiş Eski Bir Hastalık. Türk Mikrobiyoloji Cemiyeti Dergisi, 53(4).
Han, X. Y., Seo, Y. H., Sizer, K. C., Schoberle, T., May, G. S., Spencer, J. S., Nair, R. G. (2008). A new Mycobacterium species causing diffuse lepromatous leprosy. American journal of clinical pathology, 130(6), 856-864. doi: 10.1309/AJCPP72FJZZRRVMM.
Spencer JS, Brennan PJ. (2011). The role of Mycobacterium leprae phenolic glycolipid I (PGL-I) in serodiagnosis and in the pathogenesis of leprosy. Lepr Rev. Dec;82(4):344-57.
Froes LAR Junior ., Sotto, M. N.,Trindade, M. A. B. (2022). Leprosy: clinical and immunopathological characteristics. Anais brasileiros de dermatologia, 97(3), 338-347. doi: 10.1016/j.abd.2021.08.006
Ridley DS, Jopling WH. (1966). Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 34(3):255-73.
Modlin, R. L. (1994). Th1-Th2 paradigm: insights from leprosy. Journal of Investigative Dermatology, 102(6), 828-832. doi: 10.1111/1523-1747.ep12381958.
Froes, L. A. R., Sotto, M. N., Trindade, M. A. B. (2025). Leprosy in the 21st century: a comprehensive review of immunological mechanisms, diagnosis, and treatment. Revista do Instituto de Medicina Tropical de São Paulo, 67, e74. doi: 10.1590/S1678-9946202567074.
Doz-Deblauwe, É., Carreras, F., Arbues, A., Remot, A., Epardaud, M., Malaga, W., ... & Winter, N. (2019). CR3 engaged by PGL-I triggers syk-calcineurin-NFATc to rewire the innate immune response in leprosy. Frontiers in Immunology, 10, 2913. doi: 10.3389/fimmu.2019.02913. PMID: 31921172.
Silva, M. J. A., Silva, C. S., Brasil, T. P., Alves, A. K., Dos Santos, E. C., Frota, C. C., ... & Lima, L. N. G. C. (2024). An update on leprosy immunopathogenesis: systematic review. Frontiers in Immunology, 6:15: 1416177. doi: 10.3389/fimmu.2024.1416177.
18-de Sousa, J. R., Lucena Neto, F. D., Sotto, M. N., Quaresma, J. A. S. (2018). Immunohistochemical characterization of the M4 macrophage population in leprosy skin lesions. BMC infectious diseases, 15;18(1): 576. doi: 10.1186/s12879-018-3478-x.
Montoya, D., Cruz, D., Teles, R. M., Lee, D. J., Ochoa, M. T., Krutzik, S. R., ... & Modlin, R. L. (2009). Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell host & microbe, 22;6(4):343-353. doi: 10.1016/j.chom.2009.09.002.
Alrehaili, J. (2023). Leprosy classification, clinical features, epidemiology, and host immunological responses: failure of eradication in 2023. Cureus, 6;15(9). doi: 10.7759/cureus.44767.
Froes, L. A. R., Sotto, M. N., Trindade, M. A. B. (2022). Leprosy: clinical and immunopathological characteristics. Anais brasileiros de dermatologia, 97(3), 338-347. doi: 10.1016/j.abd.2021.08.006.
Souza Jd, Sousa JR, Hirai KE, Silva LM, Fuzii HT, Dias LB Jr, Carneiro FR, Aarão TL, Quaresma JA. E-selectin and P-selectin expression in endothelium of leprosy skin lesions. Acta Trop. 2015 Sep;149:227-31. doi: 10.1016/j.actatropica.2015.06.002. Epub 2015 Jun 5. PMID: 26051909.
de Sousa J, Sousa Aarão TL, Rodrigues de Sousa J, Hirai KE, Silva LM, Dias LB Jr, Oliveira Carneiro FR, Fuzii HT, Quaresma JA. Endothelium adhesion molecules ICAM-1, ICAM-2, VCAM-1 and VLA-4 expression in leprosy. Microb Pathog. 2017 Mar;104:116-124. doi: 10.1016/j.micpath.2017.01.021. Epub 2017 Jan 11. PMID: 28088473.
Dewi, D. A. R., Djatmiko, C. B. P., Rachmawati, I., Arkania, N., Wiliantari, N. M., Nadhira, F., (2023). Immunopathogenesis of Type 1 and Type 2 Leprosy Reaction: An Update Review. Cureus. 21;15(11):e49155. doi: 10.7759/cureus.49155.
Serrano-Coll, H., Wan, E. L., Restrepo-Rivera, L., Cardona-Castro, N. (2024). Leprosy reactions: unraveling immunological mechanisms underlying tissue damage in leprosy patients. Pathogens and Disease,7; 82: ftae013. doi: 10.1093/femspd/ftae013.